1.Thokala, P, Ochalek, J, Leech, AA, Tong, T (2018) Cost-effectiveness thresholds: The past, the present and the future. Pharmacoeconomics 36, 509–522.
2.Cameron, D, Ubels, J, Norstrom, F (2018) On what basis are medical cost-effectiveness thresholds set? Clashing opinions and an absence of data: A systematic review. Glob Health Action 11, 1447828.
3.Enns, MW, Reiss, JP, Chan, P (2009) Electroconvulsive therapy. Can J Psychiatry 55, 1–12.
4.Delva, NJ, Graf, P, Patry, S, et al. (2011) Access to electroconvulsive therapy services in Canada. J ECT 27, 300–309.
5.Knapp, M, Romeo, R, Mogg, A, et al. (2008) Cost-effectiveness of transcranial magnetic stimulation vs. electroconvulsive therapy for severe depression: A multi-centre randomised controlled trial. J Affect Disord 109, 273–285.
6.McLoughlin, DM, Mogg, A, Eranti, S, et al. (2007) The clinical effectiveness and cost of repetitive transcranial magnetic stimulation versus electroconvulsive therapy in severe depression: A multicentre pragmatic randomised controlled trial and economic analysis. Health Technol Assess 11, 1–54.
7.Slotema, CW, Blom, JD, Hoek, HW, Sommer, IE (2010) Should we expand the toolbox of psychiatric treatment methods to include repetitive transcranial magnetic stimulation (rTMS)? A meta-analysis of the efficacy of rTMS in psychiatric disorders. J Clin Psychiatry 71, 873–884.
8.Health Quality Ontario (2016) Repetitive transcranial magnetic stimulation for treatment-resistant depression: A systematic review and meta-analysis of randomized controlled trials. Ont Health Technol Assess Ser 16, 1–66.
9.Health Quality Ontario (2016) Repetitive transcranial magnetic stimulation for treatment-resistant depression: An economic analysis. Ont Health Technol Assess Ser 16, 1–51.
10.Walter, G, Martin, J, Kirkby, K, Pridmore, S (2001) Transcranial magnetic stimulation: Experience, knowledge and attitudes of recipients. Aust N Z J Psychiatry 35, 58–61.
11.El Shayeb, ME, Topfer, LA, Stafinski, T, Pawluk, L, Menon, D (2014) Diagnostic accuracy of level 3 portable sleep tests versus level 1 polysomnography for sleep-disordered breathing: A systematic review and meta-analysis. CMAJ 186, E25–E51.
12.Glick, HA, Briggs, AH, Polsky, D (2001) Quantifying stochastic uncertainty and presenting results of cost-effectiveness analyses. Expert Rev Pharmacoecon Outcomes Res 1, 25–36.
13.Kahneman, D, Tversky, A (1984) Choices, values, and frames. Am Psychol 39, 341.
14.Eckermann, S (2015) Kinky thresholds revisited: Opportunity costs differ in the NE and SW quadrants. Appl Health Econ Health Policy 13, 7–13.
15.O'Brien, BJ, Gertsen, K, Willan, AR, Faulkner, LA (2002) Is there a kink in consumers' threshold value for cost-effectiveness in health care? Health Econ 11, 175–180.
16.Claxton, K, Martin, S, Soares, M, et al. (2015) Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold. Health Technol Assess 19, 1–503, .
18.Wangge, G, Roes, KC, de Boer, A, Hoes, AW, Knol, MJ (2013) The challenges of determining noninferiority margins: A case study of noninferiority randomized controlled trials of novel oral anticoagulants. CMAJ 185, 222–227.
19.Xie, X, Wang, M, Ng, V, Sikich, N (2018) Some issues for the evaluation of noninferiority trials. J Comp Eff Res 7, 835–843.
20.Briggs, A, Sculpher, M, Claxton, K (2006) Decision modelling for health economic evaluation. Oxford: Oxford University Press.
21.Fenwick, E, O'Brien, BJ, Briggs, A (2004) Cost-effectiveness acceptability curves--facts, fallacies and frequently asked questions. Health Econ 13, 405–415.
22.Viechtbauer, W (2010) Conducting meta-analyses in R with the metafor package. J Stat Softw 36, 1–48.
23.Rucker, G (2012) Network meta-analysis, electrical networks and graph theory. Res Synth Methods 3, 312–324.
24.Zhao, YJ, Tor, PC, Khoo, AL, Teng, M, Lim, BP, Mok, YM (2018) Cost-effectiveness modeling of repetitive transcranial magnetic stimulation compared to electroconvulsive therapy for treatment-resistant depression in Singapore. Neuromodulation 21, 376–382.
25.Kozel, FA, George, MS, Simpson, KN (2004) Decision analysis of the cost-effectiveness of repetitive transcranial magnetic stimulation versus electroconvulsive therapy for treatment of nonpsychotic severe depression. CNS Spectr 9, 476–482.
29.Milev, RV, Giacobbe, P, Kennedy, SH, et al. (2016) Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: Section 4. Neurostimulation treatments. Can J Psychiatry 61, 561–575.
30.Bosmans, JE, de Bruijne, MC, van Hout, HP, Hermens, ML, Ader, HJ, van Tulder, MW (2008) Practical guidelines for economic evaluations alongside equivalence trials. Value Health 11, 251–258.
31.Klok, RM, Postma, MJ (2004) Four quadrants of the cost-effectiveness plane: Some considerations on the south-west quadrant. Expert Rev Pharmacoecon Outcomes Res 4, 599–601.
32.Dowie, J (2004) Why cost-effectiveness should trump (clinical) effectiveness: The ethical economics of the south west quadrant. Health Econ 13, 453–459.
33.Kent, DM, Fendrick, AM, Langa, KM (2004) New and dis-improved: On the evaluation and use of less effective, less expensive medical interventions. Med Decis Making 24, 281–286.